Oral GLP-1 formulations represent a groundbreaking advance in obesity treatment, offering improved patient comfort and ...

Liraglutide is a GLP-1 analog, which is resistant to degradation. Phase III trials have demonstrated that liraglutide effectively controls glucose levels, while reducing bodyweight.

As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as GLP-1 receptor agonists, including the popular name brands Ozempic, Wegovy, ...

These statements relate to, among other things, the anticipated benefits and impact of the AI-driven peptide discovery pipeline, the potential for computationally designed GLP-1 analogs to improve ...

In diabetes, injectable GLP-1 analog Ozempic (patent 2032) looks best-in-class over Lilly's Trulicity, and oral Rybelsus (patent 2032) expands reach into the oral diabetes treatment market.

Can GLP-1 Meds Harm Your Eyes? By Ernie Mundell HealthDay Reporter MONDAY, Feb. 10, 2025 (HealthDay News) -- Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight loss ...

But virtual diabetes and weight management care changed when GLP-1 drug Wegovy was approved for weight loss in June 2021. As the drugs' popularity reached new heights, it became an expensive item ...